Summary of Study ST002133

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001351. The data can be accessed directly via it's Project DOI: 10.21228/M83699 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002133
Study TitleMetabolite variation in the blood serum of HIV carrier patients treated with effervescent glutamine
Study TypeLiquid NMR experiments
Study SummaryIt was demonstrated that effervescent glutamine supplementation in people living with HIV/AIDS increased the amount of CD4+ T lymphocytes. , decreased the serum levels of biomarkers of inflammation, and introduced health benefits. Herein, NMR spectroscopy was applied to evaluate if oral ingestion of glutamine (12.5 g) for 30 days can be measured through serum metabolite variations and if the reported benefits might correlate to small metabolites' changes in a chosen cohort of individuals. The HIV/AIDS group has been carefully selected and studied before and after the 30-days of supplementation with the glutamine, together with the matched non-HIV carrier patients' group. The group of HIV/AIDS individuals presented lower (p < 0.05) levels of choline, creatine, pyruvate, glutamate, lysine, and tyrosine when compared to the non-HIV carrier patients. On the other hand, serum concentrations of glucose, lipids, lactate, glutamine, phenylalanine, and threonine were higher (p < 0.05) in HIV/AIDS individuals. The variation in metabolites as a result of treatment with glutamine is consistent with the improvements observed in these patients and may lead us to suggest the introduction of the effervescent glutamine supplementation to antiretroviral therapies in people living with HIV/AIDS.
Institute
University of Campinas
DepartmentOrganic Chemistry
LaboratoryBiological Chemistry Lab
Last NameMARTINS
First NameLUCAS
AddressRua Josué de Castro, s/n - Cidade Universitária, Campinas - SP, 13083-970
Emaillgmartins1984@gmail.com
Phone+5519992947044
Submit Date2022-03-31
Num Groups3
Total Subjects24
Num Males10
Num Females14
Study CommentsCrossover study
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2022-04-27
Release Version1
LUCAS MARTINS LUCAS MARTINS
https://dx.doi.org/10.21228/M83699
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001351
Project DOI:doi: 10.21228/M83699
Project Title:Untargeted metabolomics of HIV carrier patients
Project Type:NMR-based metabolomics
Project Summary:Analysis of metabolite variation in HIV carrier patients blood serum in response to treatment with effervescent glutamine.
Institute:University of Campinas
Department:Organic Chemistry
Laboratory:Biological Chemistry Lab
Last Name:Martins
First Name:Lucas
Address:Cidade Universitário Zeferino Vaz, Campinas, SP, Brazil
Email:lgmartins1984@gmail.com
Phone:+5519992947044
Funding Source:FAPESP, INCT-Bio

Subject:

Subject ID:SU002218
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:40.3 ± 3.9
Human Nutrition:Effervecent glutamine administration (12.5g, once a day for 30 days)
Human Inclusion Criteria:Patients living with HIV from Public Service Health Care for Sexually Transmitted Diseases/AIDS Center of Maringá City, Paraná, Brazil, with same ART treatment for at least 1 year.
Human Exclusion Criteria:Patients which were transferred, who abandoned treatment, and those who had not been evaluated for viral load and CD4+ T lymphocyte counts were excluded.

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample class
SA20477812pos1AT
SA20477913pos1AT
SA20478015pos1AT
SA20478110pos1AT
SA20478214pos1AT
SA2047838pos1AT
SA2047842pos1AT
SA2047854pos1AT
SA2047866pos1AT
SA20478717pos1AT
SA2047889pos1AT
SA2047894pos2AT
SA20479014pos2AT
SA20479115pos2AT
SA20479216pos2AT
SA20479317pos2AT
SA20479413pos2AT
SA20479512pos2AT
SA2047961pos1AT
SA2047976pos2AT
SA2047988pos2AT
SA20479910pos2AT
SA2048001pos2AT
SA20480117pre2BT
SA20480212pre1BT
SA20480313pre1BT
SA20480416pre1BT
SA20480514pre1BT
SA20480610pre1BT
SA2048079pre1BT
SA2048082pre1BT
SA2048094pre1BT
SA2048106pre1BT
SA2048118pre1BT
SA20481217pre1BT
SA2048132pre2BT
SA20481413pre2BT
SA20481514pre2BT
SA20481615pre2BT
SA20481716pre2BT
SA20481812pre2BT
SA20481910pre2BT
SA2048204pre2BT
SA2048216pre2BT
SA2048228pre2BT
SA2048239pre2BT
SA2048241pre1BT
Showing results 1 to 47 of 47

Collection:

Collection ID:CO002211
Collection Summary:Serum samples were obtained from 12 HIV/AIDS patients before (day 0) and after glutamine (day 31) administration, and from healthy donors.
Sample Type:Blood (serum)
Storage Conditions:-80℃

Treatment:

Treatment ID:TR002230
Treatment Summary:Glutamine supplementation (12.5g/day for 30 days)

Sample Preparation:

Sampleprep ID:SP002224
Sampleprep Summary:Serum samples were carefully separated and aliquoted in duplicates (250 μL each one) into cryovials and stored at -80 °C. Samples (250 μL) were thawed on ice, mixed with 250 μL of deuterium oxide (D2O 99.9%, Cambridge Isotope Laboratories, Inc., Andover, USA) at room temperature, centrifuged at 12,000 × g for 2 min at 4 °C, and transferred into 5 mm NMR tubes
Processing Storage Conditions:-80℃

Analysis:

Analysis ID:AN003488
Analysis Type:NMR
Results File:ST002133_AN003488_Results.txt
Units:intensity

NMR:

NMR ID:NM000236
Analysis ID:AN003488
Instrument Name:Avance 600 Bruker
Instrument Type:FT-NMR
NMR Experiment Type:1D-1H
Spectrometer Frequency:600 MHz for 1H
NMR Probe:inverse triple-core probe (TBI)
NMR Solvent:H2O/D2O
NMR Tube Size:5 mm
  logo